Pediatric Asthma Programs With CyDex, Inc. Captisol Technology Acquired by AstraZeneca PLC

October 3, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc. today announced that rights to pediatric asthma development programs that include CyDex’s Captisol-Enabled® technology have been acquired from Verus Pharmaceuticals, Inc. by AstraZeneca.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions

AstraZeneca